RB Pharma SPRL
RB Pharma reported revenue of 381,827 € for the 2025 financial year (annual accounts filed with the NBB on 29 Jun 2026).
The score of RB Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -31 % Total assets +57 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
RB Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 381,827 € | ||||
| Net result | −24,303 € | ||||
| Equity | 141,141 € | ||||
| Cash | 49,458 € | ||||
| EBITDA | 12,007 € | ||||
| Total assets | 391,281 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Jun 2026
- Year ended 31 Dec 2024filed on 23 Jul 2025
- Year ended 31 Dec 2023filed on 09 Jul 2024
- Year ended 31 Dec 2022filed on 05 Sep 2023
- Year ended 31 Dec 2021filed on 19 Sep 2022
RB Pharma's financial analysis
- Solvency36.1%sector median: 50.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of RB Pharma
RB Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0504.849.465
- VAT number
- BE0504849465
- Peppol
- Registered · 0208:0504849465 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 12 Feb 2013
- Registered office
- 4030 Liège
- Latest accounts
- 2025 · filed on 29 Jun 2026
- Activity
- Business and other management consultancy activities (NACE 70200)
RB Pharma (SPRL) has been based in Liège since 2013, active in: business and other management consultancy activities. For 2025, it reports revenue of 381,827 €, a net loss of 24,303 € and equity of 141,141 €. Its solvency stands at 36.1%, below the median of its sector (50.1%).
Companies similar to RB Pharma
Companies in the same business, of comparable size and area, outside its group.
- J.R. Econsult Business and other management consultancy activities Kinrooi · balance sheet 387,784 €
- BE & Partners Business and other management consultancy activities Geel · balance sheet 380,259 €
- RLM Consulting Business and other management consultancy activities Ottignies-Louvain-la-Neuve · balance sheet 505,827 €
- Klareco Business and other management consultancy activities Kraainem · balance sheet 287,301 €
- TOM Lenaerts Consultancy Business and other management consultancy activities Geel · balance sheet 555,556 €
- Connected For Tomorrow All other professional, scientific and technical activities n.e.c. Brussels · balance sheet 371,367 €
- Tender Expert 2.0 Business and other management consultancy activities Wemmel · balance sheet 669,843 €
- Medisch Pharmaceutische Informatie Business and other management consultancy activities Zemst · balance sheet 225,974 €
Frequently asked questions about RB Pharma
What is the revenue of RB Pharma?
According to the 2025 annual accounts filed with the NBB, the revenue of RB Pharma amounts to 381,827 €.
What is the VAT number of RB Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0504849465 for RB Pharma, if the company is VAT-registered. Its company number (CBE) is 0504.849.465.
Where is the registered office of RB Pharma?
According to the CBE register, the registered office of RB Pharma is in 4030 Liège.
What is the equity of RB Pharma?
At the close of the 2025 financial year, the equity of RB Pharma amounts to 141,141 €, a solvency of 36.1% of total assets.
Who manages RB Pharma?
The register lists 1 active mandates at RB Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of RB Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →